Tonghua Dongbao 2024 annual results pre-reduction announcement

SZSI00:00 · Announcements

An new low in eighteen years! Tonghua Dongbao Pharmaceutical expects last year's net income to decline by more than 90% year-on-year, and Q4 performance may not meet expectations | Interpretations

① Affected by the decline in sales revenue due to product price reductions, as well as the termination of research and development projects, Tonghua Dongbao Pharmaceutical expects that its net income attributable to the parent for 2024 will decrease by more than 90% year-on-year. ② Compared to Q4, net income saw a decline quarter-on-quarter, and may not have met the company's previous expectations.

cls.cnJan 20 21:40

Express News | Tonghua Dongbao Pharmaceutical: It is expected that the net income in 2024 will decrease by approximately 96.53% year-on-year.

BreakingsJan 20 16:25

Tonghua Dongbao Pharmaceutical (600867.SH): Obtained上市许可 for the product Koxilin tablets.

On January 20, Gelonghui reported that Tonghua Dongbao Pharmaceutical (600867.SH) announced it has recently received the pharmaceutical registration certificate for Etoricoxib tablets issued by the National Medical Products Administration. Etoricoxib tablets are a new generation of selective cyclooxygenase-2 (COX-2) inhibitors, which possess anti-inflammatory, analgesic, and antipyretic effects, and compared to traditional drugs, they have fewer gastrointestinal side effects, lack sulfonamide groups, and are safer for patients allergic to sulfonamides. Etoricoxib is widely used clinically, including for osteoarthritis, primary dysmenorrhea, and acute gouty arthritis, and is currently the only drug approved in China for the treatment of acute gouty arthritis.

Gelonghui FinanceJan 20 15:36

Wang Junye, the chairman of the supervisory board of Tonghua Dongbao Pharmaceutical (600867.SH), has cumulatively increased his shareholding in the company by 0.5082 million shares.

Tonghua Dongbao Pharmaceutical (600867.SH) announced that as of January 15, 2025, the chairman of the supervisory committee, Wang Junye...

Zhitong FinanceJan 15 15:32

Tonghua Dongbao Unit Starts Phase 2 Clinical Study for Anti-Obesity Injection

MT NewswiresJan 14 19:23